Evidence map›Paper›PMID 32617727›Full record

ArticleJournal of biomolecular NMR2020

NMR spectroscopy: the swiss army knife of drug discovery.

Reto Horst, Kathleen A Farley, Bethany L Kormos, Jane M Withka

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of biomolecular NMR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Molecules (Basel, Switzerland) · 2024
    Article
  4. Article
  5. NMR in pharmaceutical discovery and development.Journal of biomolecular NMR · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Reto HorstMedicinal Sciences, Pfizer, Eastern Point Road, Groton, CT, 06340, USA. reto.horst@pfizer.com.ORCID http://orcid.org/0000-0002-2684-0310
Kathleen A FarleyMedicinal Sciences, Pfizer, Eastern Point Road, Groton, CT, 06340, USA.
Bethany L KormosMedicinal Sciences, Pfizer, 610 Main St., Cambridge, MA, 02139, USA.
Jane M WithkaMedicinal Sciences, Pfizer, 610 Main St., Cambridge, MA, 02139, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nuclear magnetic resonance (NMR) spectroscopy has evolved into a powerful tool within drug discovery over the last two decades. While traditionally being used by medicinal chemists for small molecule structure elucidation, it can also be a valuable tool for the identification of small molecules that bind to drug targets, for the characterization of target-ligand interactions and for hit-to-lead optimization. Here, we describe how NMR spectroscopy is integrated into the Pfizer drug discovery pipeline and how we utilize this approach to identify and validate initial hits and generate leads.

Indexed as

Crystallography, X-RayDrug DesignDrug DiscoveryHigh-Throughput Screening AssaysLigandsModels, MolecularMolecular ConformationNuclear Magnetic Resonance, BiomolecularProtein BindingSmall Molecule LibrariesSolutionsLigandsSmall Molecule LibrariesSolutionsDrug designFragment based drug discoveryNMRResidual dipolar couplingsSmall molecule solution conformations

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.